GlassScriptPhysician profile
Ali A Valika
NPI 1760696314
$217,798.83
in general payments reported to CMS, 2019-2025
41 companies · $52K in 2025
The $52K reported for 2025 was more than what 93% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $19K · 2021: $26K · 2022: $31K · 2023: $39K · 2024: $20K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $90K · Food and Beverage: $9,240 · Travel and Lodging: $6,090 · Consulting Fee: $5,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $89,759.00 |
| Food and Beverage | $9,239.74 |
| Travel and Lodging | $6,089.62 |
| Consulting Fee | $5,460.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $58,463.78 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $48,869.11 | 2019-2025 | Camzyos |
| Abbott Laboratories | $20,935.88 | 2019-2025 | Cardiomems, 2nd Gen Centrimag Primary Console, Thoratec Heartmate 3 Lvas Implant Kit |
| Novartis Pharmaceuticals Corporation | $17,319.84 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $15,801.92 | 2025 | |
| Pfizer INC. | $14,943.62 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $12,391.00 | 2020-2025 | Farxiga |
| Lilly USA, LLC | $12,372.50 | 2020-2025 | Jardiance |
| Scpharmaceuticals INC. | $4,271.12 | 2023 | |
| Alnylam Pharmaceuticals INC. | $3,630.00 | 2019 | |
| Ancora Heart, INC. | $3,478.99 | 2022-2025 | Accucinch |
| Abiomed | $1,057.62 | 2019-2025 | Impella |
| Novo Nordisk INC | $656.17 | 2019-2025 | Wegovy |
| Cardiac Dimensions, INC. | $490.54 | 2023-2024 | |
| Cvrx, INC. | $481.57 | 2021-2025 | Barostim Neo System |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $317.39 | 2023-2025 | Pascal, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $247.25 | 2023-2025 | Watchman Access System, Watchman Flx |
| Nuwellis, INC. | $217.10 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $200.69 | 2023-2025 | Uptravi, Opsumit |
| Amgen INC. | $190.34 | 2019-2024 | Repatha |
| Endotronix, INC. | $156.17 | 2023-2025 | Cordella Pulomonary Artery Pressure Sensor |
| Itamar Medical INC | $138.21 | 2022 | |
| Medtronic Vascular, INC. | $131.55 | 2019 | |
| Bridgebio Pharma, INC. | $126.38 | 2025 | Attruby |
| Zoll Respicardia, INC. | $115.20 | 2021 | |
| Livanova USA, INC. | $99.65 | 2019 | |
| La Jolla Pharmaceutical Company | $97.75 | 2019 | |
| Philips North America LLC | $94.54 | 2022-2023 | |
| Teleflex LLC | $70.98 | 2025 | Turnpike, Trapliner |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $59.32 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $54.71 | 2019 | |
| Terumo Medical Corporation | $53.74 | 2019-2021 | |
| Heartflow, INC. | $50.77 | 2025 | |
| Janssen Scientific Affairs, LLC | $49.90 | 2020 | |
| Glaxosmithkline, LLC. | $45.53 | 2021 | |
| Impulse Dynamics (USA) INC. | $37.97 | 2025 | Optimizer |
| United Therapeutics Corporation | $25.56 | 2019 | |
| Medtronic, INC. | $21.25 | 2021 | |
| Cordis US Corp. | $19.13 | 2024 | Mynxgrip |
| Sanofi-Aventis U.S. LLC | $14.09 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Valika listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.